{"id":543259,"date":"2010-04-26T08:41:37","date_gmt":"2010-04-26T12:41:37","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=75814"},"modified":"2010-04-26T08:41:37","modified_gmt":"2010-04-26T12:41:37","slug":"novartis-buys-more-alnylam-shares","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/543259","title":{"rendered":"Novartis Buys More Alnylam Shares"},"content":{"rendered":"\n
Biotech<\/a>, Finances<\/a>, deals<\/a><\/div>\n

\t\tLuke Timmerman wrote:<\/strong><\/p>\n

Pharmaceutical giant Novartis has exercised its right to buy 55,223 more shares of Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY<\/a>), Alnylam said today in a statement<\/a>. The purchases, for almost $1 million, allow Novartis to maintain a 13.4 percent ownership stake in the company, Alnylam said. The two companies began collaborating on RNA interference technology in 2005, and the collaboration has been extended to last through October 2010.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

UNDERWRITERS AND PARTNERS
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t<\/p>\n

\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t\t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Biotech, Finances, deals Luke Timmerman wrote: Pharmaceutical giant Novartis has exercised its right to buy 55,223 more shares of Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY), Alnylam said today in a statement. The purchases, for almost $1 million, allow Novartis to maintain a 13.4 percent ownership stake in the company, Alnylam said. The two companies began […]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-543259","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/543259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=543259"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/543259\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=543259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=543259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=543259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}